Arif Nur Muhammad Ansori; Ahmad Affan Ali Murtadlo; Viol Dhea Kharisma; Bayyinatul Muchtaromah; Muhammad Badrut Tamam; Dora Dayu Rahma Turista; Imam Rosadi; Vikash Jakhmola; Tarun Parashar; Taru Saklani; Maksim Rebezov; Rahadian Zainul; Hery Purnobasuki; Amaq Fadholly; Muhammad Kusala
Abstract
The global health landscape has seen an upsurge in viral diseases, underlining the urgency for novel antiviral therapies. This mini-review illuminates the potential antiviral capabilities ...
Read More
The global health landscape has seen an upsurge in viral diseases, underlining the urgency for novel antiviral therapies. This mini-review illuminates the potential antiviral capabilities of gamma-mangostin, a xanthone derivative derived from the pericarp of the Garcinia mangostana fruit. Gamma-mangostin's mechanisms of action are multifaceted, displaying inhibitory effects on viral entry into host cells, disrupting essential cell signalling pathways for viral replication, and enhancing the host's immune response via antiviral cytokine stimulation. This compound has demonstrated significant in vitro efficacy against numerous viruses, including Influenza A virus, Herpes simplex virus, and Hepatitis C virus, and emerging preliminary research suggests potential utility against SARS-CoV-2. Its broad-spectrum antiviral properties and low cytotoxicity earmark gamma-mangostin as a promising candidate for future antiviral agent development. However, rigorous investigation is required to determine its pharmacokinetics, bioavailability, and safety profile. With the escalating burden of viral diseases, gamma-mangostin could represent an important tool in the armamentarium for disease management, contingent upon further study. This review provides an overview of current research into gamma-mangostin's antiviral potential and the challenges to its therapeutic development.